Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Future Oncol
; 11(12): 1729-39, 2015.
Article
em En
| MEDLINE
| ID: mdl-26075441
ABSTRACT
The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Biespecíficos
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article